| Identification | Back Directory | [Name]
raceMic-Tasocitinib | [CAS]
1259404-17-5 | [Synonyms]
raceMic-Tasocitinib
racemic-tofacitinib
1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R)-rel-
3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3r,4r)-rel- | [Molecular Formula]
C16H20N6O | [MDL Number]
MFCD22628813 | [MOL File]
1259404-17-5.mol | [Molecular Weight]
312.37 |
| Chemical Properties | Back Directory | [density ]
1.296±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [pka]
-0.533±0.60(predicted) |
| Hazard Information | Back Directory | [Definition]
ChEBI: Tofacitinib is a pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor and an antirheumatic drug. It is a pyrrolopyrimidine, a N-acylpiperidine, a nitrile and a tertiary amino compound. |
|
|